J Neurol Surg B Skull Base 2014; 75(06): 409-414
DOI: 10.1055/s-0034-1378151
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Radiosurgery is an Effective Treatment for Recurrent Esthesioneuroblastoma: A Multicenter Study

Jamie J. Van Gompel
1   Departments of Neurosurgery, Mayo Clinic, Rochester, Minnesota, United States
,
Michael J. Link
1   Departments of Neurosurgery, Mayo Clinic, Rochester, Minnesota, United States
,
Jason P. Sheehan
2   Department of Neurosurgery, University of Virginia Health System, Charlottesville, Virginia, United States
,
Zhiyuan Xu
2   Department of Neurosurgery, University of Virginia Health System, Charlottesville, Virginia, United States
,
David Mathieu
3   Department of Neurosurgery, University of Sherbrooke, Centre de Recherche Clinique Étienne-LeBel, Sherbrooke, Quebec, Canada
,
Hideyuki Kano
4   Department of Neurosurgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
,
L. Dade Lunsford
4   Department of Neurosurgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
› Author Affiliations
Further Information

Publication History

05 January 2014

15 April 2014

Publication Date:
04 June 2014 (online)

Preview

Abstract

Objective Esthesioneuroblastoma (ENB) is a rare malignant neuroendocrine neoplasm that is prone to both local and metastatic recurrence. Local recurrence may often be treated with repeat resection. However, stereotactic radiosurgery (SRS) offers a noninvasive option.

Design Prospective database review.

Participants Gamma knife prospective databases were queried at all institutions within the North American Gamma Knife Consortium, 16 at the time of this report. All patients who had undergone SRS for ENB were included.

Main Outcome Measure Response of recurrent ENB to SRS.

Results A total of 31 locally recurrent tumors in 13 patients were treated with SRS. The median age was 49 years (range: 19–79 years). At a median follow-up of 36 months (range: 1–100 months), 13 (48%) treated tumors were smaller, 11 (41%) were stable, and 3 (11%) showed continued growth following SRS. Univariate analysis did not find any significant factor relating to failure of treatment. Notably, no treatment-related complications (0%) were observed in this cohort.

Conclusion SRS appears to provide a safe and effective option for treatment of recurrent intracranial ENB. Overall, 89% of treated tumors were controlled in this multi-institutional study.